Study guide

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package

Key Takeaways Explain This Topic AI

Chadwick (bluish cervix and vagina), Hegar (soft lower uterine segment) and Goodell (soft cervix) signs are probable signs of pregnancy; fetal heart tones, fetal movements felt by the examiner and ultrasound are positive signs.

Normal pregnancy causes dilutional anemia, a 30% to 50% rise in cardiac output, lower vascular resistance, compensated respiratory alkalosis (pCO2 27 to 32 mmHg) and a 50% rise in GFR.

Naegele's rule estimates the due date as LMP plus 7 days minus 3 months plus 1 year; first-trimester crown-rump length is the most accurate dating method.

The DOH antenatal standard is at least eight contacts (one in the first trimester, two in the second, five in the third) with daily iron 60 mg plus folic acid 400 mcg for 180 days.

Teratogens to avoid include isotretinoin, warfarin, valproate, ACE inhibitors, tetracyclines, alcohol and smoking; raw or high-mercury fish and unpasteurized foods are restricted.

Last updated: October 2026

Why this area matters

TOS area B asks you to:

recognize the burden of unplanned pregnancy;

describe the physiologic changes of pregnancy, prenatal nutrition and supplements, routine laboratory tests and the schedule of prenatal consultations;

  • recognize signs of normal and abnormal fetal development;
  • counsel against toxicants, pollutants and unsafe foods;

choose screening and diagnostic tests that detect fetal anomalies and maternal risks.

Early, regular antenatal care is the foundation of the DOH maternal health program. Complications found early (anemia, hypertension, diabetes, infection, malpresentation) can be managed or referred before labor. Unplanned pregnancies, especially among adolescents, often start care late, so every visit is also a chance to plan the next pregnancy.

Diagnosis of pregnancy

Category Signs

Presumptive (reported by the woman) Amenorrhea, nausea and vomiting, breast tenderness, urinary frequency, fatigue, quickening (first fetal movements felt at about 18 to 20 weeks in a first pregnancy, earlier in multiparas)

Probable (found by the examiner) Chadwick sign (bluish discoloration of the cervix and vagina), Hegar sign (softening of the lower uterine segment), Goodell sign (softening of the cervix), uterine enlargement, Braxton Hicks contractions, ballottement, positive hCG test

Positive (proof of a fetus) Fetal heart tones (Doppler from about 10 to 12 weeks), fetal movements felt by the examiner , visualization of the fetus on ultrasound

hCG is made by the syncytiotrophoblast. It roughly doubles every 48 hours in early viable pregnancy and peaks at 8 to 10 weeks.

A gestational sac is seen on transvaginal ultrasound at about 4.5 to 5 weeks, a yolk sac at about 5.5 weeks and cardiac activity at about 6 weeks.

Maternal Physiologic Adaptations to Pregnancy

Pregnancy triggers profound systemic anatomical and physiologic alterations designed to support embryonic growth, optimize fetal oxygenation, and prepare the maternal organism for parturition.

Cardiovascular Alterations

Plasma Volume and Hematology: Maternal blood volume increases by 40% to 50% above non-pregnant levels, beginning as early as 6 weeks of gestation and peaking between 28 and 32 weeks. Erythrocyte mass increases by only 20% to 30%, driven by elevated erythropoietin. This disproportionate fluid expansion results in physiologic dilutional anemia of pregnancy . Normal hemoglobin thresholds shift downward: the lower limit of normal is 11.0 g/dL in the first and third trimesters, and 10.5 g/dL in the second trimester.

Cardiac Output: Cardiac output ( C O = H R × S V CO = HR \times SV CO = H R × S V ) increases by 30% to 50%. In early pregnancy, this rise is primarily driven by an increased stroke volume (SV). Later in gestation, resting heart rate increases by 10 to 15 beats per minute (bpm). Cardiac output peaks immediately postpartum due to autotransfusion from the contracted uterus and relief of inferior vena cava compression.

Systemic Vascular Resistance (SVR) and Blood Pressure: High levels of circulating progesterone, along with enhanced endothelial release of nitric oxide and prostacyclin ( P G I 2 PGI_2 PG I 2 ​ ), induce widespread vascular smooth muscle relaxation. Consequently, SVR falls by up to 30%. Maternal blood pressure declines early in the first trimester, reaching a nadir at 24 to 28 weeks of gestation (diastolic pressure typically drops by 10 to 15 mmHg), before gradually returning to non-pregnant baseline levels at term.

Supine Hypotensive Syndrome: In the supine position after mid-gestation, the gravid uterus compresses the inferior vena cava (IVC) and descending aorta. This reduces venous return to the right atrium, precipitously lowering cardiac output and causing maternal hypotension, diaphoresis, syncope, and fetal bradycardia. It is rapidly alleviated by placing the patient in the left lateral decubitus position .

Respiratory Adaptations

Progesterone exerts a direct stimulatory effect on the medullary respiratory center, increasing respiratory drive.

Ventilatory Mechanics: Diaphragmatic elevation of up to 4 cm occurs as the gravid uterus expands, reducing Functional Residual Capacity (FRC) and residual volume by approximately 20%. Compensatory flaring of the lower ribs broadens the subcostal angle and increases chest circumference.

Minute Ventilation and Acid-Base Status: Maternal respiratory rate remains essentially unchanged, but tidal volume ( V T V_T V T ​ ) increases by 30% to 40%. This drives a 30% to 50% increase in minute ventilation, causing chronic physiologic hyperventilation. Arterial blood gas (ABG) analysis in normal pregnancy reveals a compensated chronic respiratory alkalosis :

  • Arterial pH: 7.40 to 7.45
  • p CO 2 p\text{CO}_2 p CO 2 ​ : 27 to 32 mmHg
  • Plasma HCO 3 − \text{HCO}_3^- HCO 3 − ​ : 18 to 22 mEq/L (due to compensatory renal excretion of bicarbonate)
  • p O 2 p\text{O}_2 p O 2 ​ : 100 to 105 mmHg

This physiologic maternal hypocapnia creates a steep transplacental carbon dioxide concentration gradient, facilitating the diffusion of C O 2 CO_2 C O 2 ​ from fetal blood into maternal circulation.

Renal and Urinary Adaptations

Renal Hemodynamics: Renal plasma flow increases by up to 75%, and Glomerular Filtration Rate (GFR) rises by 50% starting in the first trimester. This marked hyperfiltration lowers normal serum markers:

Normal pregnancy serum creatinine: about 0.4 to 0.8 mg/dL ; a value above about 0.9 mg/dL is abnormal for pregnancy and suggests renal disease.

Normal pregnancy Blood Urea Nitrogen (BUN): 8 to 10 mg/dL.

Anatomical Dilation: Progesterone-induced smooth muscle relaxation, combined with mechanical compression by the dextrorotated gravid uterus at the pelvic brim, causes physiologic hydroureter and hydronephrosis (predominantly right-sided). This urinary stasis significantly increases the risk of progression from asymptomatic bacteriuria to acute pyelonephritis.

Glucosuria and Proteinuria: Filtered glucose load exceeds tubular reabsorptive capacity, producing mild physiologic glucosuria. Normal urinary protein excretion rises up to 300 mg per 24 hours.

Hematologic and Hemostatic Changes

Pregnancy represents an acquired hypercoagulable state:

Marked increases occur in fibrinogen (Factor I, doubling to 400-600 mg/dL), Factors VII, VIII, IX, X, XII, and von Willebrand factor.

Protein S levels decrease, and resistance to activated protein C increases.

Fibrinolytic activity is suppressed antepartum, recovering rapidly after placental separation.

These changes serve as an evolutionary adaptation to prevent exsanguination during placental detachment, but they elevate the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) fivefold antepartum and up to twentyfold in the postpartum puerperium.

Mild leukocytosis is normal during gestation (white blood cell count 5,000 to 12,000/ μ L \mu\text{L} μ L ), rising up to 25,000/ μ L \mu\text{L} μ L or higher during active labor and the immediate postpartum period without signifying infection.

Organ System Key Physiologic Adaptation Direction of Change Clinical Board Implication

Cardiovascular Plasma volume vs Red cell mass Increase: PV (+50%) > RBC (+25%) Physiologic dilutional anemia (normal Hb nadir ≥ 10.5 g/dL \ge 10.5\text{ g/dL} ≥ 10.5 g/dL )

Cardiovascular Cardiac output ( C O CO CO ) Increased 30% to 50% Peaks immediately postpartum; high risk for decompensation in mitral stenosis

Cardiovascular Systemic Vascular Resistance Decreased 20% to 30% Mid-trimester BP drop; nadir at 24-28 weeks

Respiratory Minute ventilation ( V E V_E V E ​ ) Increased 30% to 50% (increased V T V_T V T ​ ) Compensated respiratory alkalosis ( p CO 2 p\text{CO}_2 p CO 2 ​ 27-32 mmHg, HCO 3 − \text{HCO}_3^- HCO 3 − ​ 18-22 mEq/L)

Renal Glomerular Filtration Rate (GFR) Increased 50% Serum creatinine above about 0.9 mg/dL suggests renal disease

Renal Ureteral dilation Right > Left dilation Urinary stasis; untreated asymptomatic bacteriuria leads to pyelonephritis

Hematology Procoagulant factors Increased (Fibrinogen, VII, VIII, X) 5x increased risk of venous thromboembolism

Antenatal Care, Dating & Clinical Surveillance

Comprehensive antenatal care aims to detect risk factors, screen for congenital and maternal disease, and optimize maternal and neonatal outcomes.

Gestational Age Dating and Clinical Assessment

Naegele's Rule: In women with regular 28-day menstrual cycles, the Estimated Date of Confinement (EDC) is calculated from the first day of the Last Normal Menstrual Period (LNMP): EDC = LNMP + 7 days − 3 months + 1 year \text{EDC} = \text{LNMP} + 7\text{ days} - 3\text{ months} + 1\text{ year} EDC = LNMP + 7 days − 3 months + 1 year

Ultrasonic Dating: First-trimester transvaginal ultrasound measuring the crown-rump length (CRL) is the single most accurate method for establishing gestational age (margin of error ± 3 to 5 days \pm 3\text{ to } 5\text{ days} ± 3 to 5 days ). When ultrasound dating differs from menstrual dating by more than 5 days before 9 weeks, or more than 7 days between 9 and 14 weeks, the ultrasound date supersedes the LNMP.

McDonald's Rule (Fundal Height Measurement): The distance from the superior border of the pubic symphysis to the top of the uterine fundus correlates with gestational age in centimeters between 20 and 36 weeks (gestational age in weeks ≈ \approx ≈ fundal height in cm ± 2 cm \pm 2\text{ cm} ± 2 cm ):

12 weeks: Uterus palpable just above the pubic symphysis.

16 weeks: Fundus midway between the pubic symphysis and the umbilicus.

20 weeks: Fundus at the level of the umbilicus (20 cm).

36 weeks: Fundus at the xiphoid process.

Leopold's Maneuvers: A systematic four-step abdominal palpation protocol performed after 28 weeks:

First Maneuver (Fundal Grip): Identifies which fetal pole occupies the uterine fundus. The fetal head is hard, round, smooth, and ballottable; the breech is softer, irregular, nodular, and non-ballottable.

Second Maneuver (Umbilical Grip): Palpates the lateral uterine walls to locate the fetal back (firm, convex, smooth resistance) and fetal small parts (irregular, nodular extremities).

Third Maneuver (Pawlik's Grip): Grasps the lower uterine pole above the pubic symphysis using the thumb and fingers of one hand to determine whether the presenting part is engaged within the pelvic inlet.

Fourth Maneuver (Pelvic Grip): The examiner faces the patient's feet and presses deep into the lower quadrants toward the pelvic inlet to confirm presentation, assess the degree of cephalic descent, and identify the cephalic prominence.

Evidence-Based Antenatal Screening Schedule

First Trimester (Initial Visit): Complete Blood Count (CBC), blood typing and Rh antibody screen, Urinalysis and quantitative urine culture (screening for asymptomatic bacteriuria), Rubella IgG titer, Hepatitis B surface antigen (HBsAg), rapid plasma reagin (RPR) or VDRL for syphilis, HIV screening.

24 to 28 Weeks of Gestation:

Screening for Gestational Diabetes Mellitus (GDM) using the 75g 2-hour Oral Glucose Tolerance Test (OGTT).

Repeat CBC for maternal anemia screening.

Repeat antibody screen in Rh-negative unsensitized women; administer Rho(D) immune globulin (300 μ g \mu\text{g} μ g ) at 28 weeks.

36 to 37 Weeks of Gestation: Universal screening for Group B Streptococcus (GBS, Streptococcus agalactiae ) via a single combined swab of the lower vagina and rectum (through the anal sphincter). Intrapartum antibiotic prophylaxis (IV Crystalline Penicillin G 5 million units loading dose, then 2.5-3.0 million units q4h until delivery; or IV Ampicillin 2g loading then 1g q4h) is administered during labor if:

Positive GBS rectovaginal screening culture in the current pregnancy.

Documented GBS bacteriuria at any time during the current pregnancy.

History of a previous infant with invasive early-onset GBS sepsis.

Unknown GBS status with risk factors: labor < 37 <37 < 37 weeks, intrapartum fever ≥ 38.0 ∘ C \ge 38.0^\circ\text{C} ≥ 38. 0 ∘ C ( 100.4 ∘ F 100.4^\circ\text{F} 100. 4 ∘ F ), or rupture of membranes ≥ 18 \ge 18 ≥ 18 hours.

The DOH antenatal care package

Schedule: at least eight antenatal contacts , at least one in the first trimester, two in the second and five in the third . This replaced the older minimum of four visits.

Records: visits are recorded in the Mother and Child Book . PhilHealth covers antenatal care in accredited facilities.

Supplements:

iron 60 mg elemental with folic acid 400 mcg once daily for 6 months (180 tablets) , started as soon as pregnancy is diagnosed;

calcium carbonate where dietary calcium is low, which also reduces preeclampsia risk;

iodized salt .

Folic acid ideally starts before conception to prevent neural tube defects : 400 mcg daily, or 4 mg daily after a previous NTD-affected pregnancy.

Tetanus-diphtheria (Td) immunization: pregnant women without documented doses get the 5-dose schedule. Two doses at least 4 weeks apart, the second given at least 2 weeks before delivery, protect the newborn against neonatal tetanus .

Counseling at each visit:

danger signs: vaginal bleeding, severe headache or blurred vision, convulsions, fever, severe abdominal pain, reduced fetal movement and leaking of fluid;

a birth plan for facility-based delivery with a skilled birth attendant;

breastfeeding and postpartum family planning.

Nutrition, weight gain and things to avoid

Recommended weight gain depends on pre-pregnancy BMI:

  • underweight: 12.5 to 18 kg;
  • normal weight: 11.5 to 16 kg;
  • overweight: 7 to 11.5 kg;

obese: 5 to 9 kg.

An extra 300 kcal per day is needed in the second and third trimesters.

Foods: avoid alcohol, raw or undercooked meat and eggs, and unpasteurized milk and soft cheese ( Listeria , Toxoplasma ). Limit large predatory fish because of their mercury . Limit caffeine to about 200 mg per day.

Toxicants and pollutants:

  • tobacco smoke, including secondhand smoke, causes low birth weight and abruption;
  • lead from batteries and old paint impairs neurodevelopment;
  • mercury from small-scale gold mining and contaminated fish damages the fetal brain;

pesticides, solvents and ionizing radiation are other exposures.

Drugs with known teratogenic effects:

  • isotretinoin : craniofacial and cardiac defects;
  • warfarin : nasal hypoplasia and stippled epiphyses;
  • valproate : neural tube defects;
  • phenytoin: fetal hydantoin syndrome;
  • ACE inhibitors and ARBs : renal dysgenesis and oligohydramnios;
  • tetracyclines : teeth discoloration;
  • methotrexate;

thalidomide: limb defects.

Screening for fetal abnormalities

First-trimester screening (11 to 14 weeks): nuchal translucency plus PAPP-A and free beta-hCG. In trisomy 21, PAPP-A is low and hCG is high.

Second-trimester quadruple test (15 to 22 weeks): in trisomy 21, AFP and estriol are low while hCG and inhibin A are high. A raised maternal serum AFP suggests an open neural tube or abdominal wall defect, multiple gestation or wrong dates.

Cell-free DNA testing is the most sensitive screening test for common trisomies.

Diagnostic tests: chorionic villus sampling (10 to 13 weeks) and amniocentesis (from 15 weeks).

Anomaly ultrasound at 18 to 22 weeks surveys fetal structure and the placenta. Fundal height that lags by more than 3 cm, or poor weight gain, prompts an ultrasound for growth restriction or oligohydramnios.